ethylenediamine
Ethylenediamine is a strongly basic amine useful as a building block in chemical synthesis. It is used as a solvent to dissolve proteins such as albumins, casein and in medicine to stabilize aminophylline when used in injections. Ethylenediamine is used in manufacture of chelating agents (EDTA), epoxy curing agents, dimethylolethylene-urea resins, emulsifying agents, textile lubricants, antifreeze inhibitor. It is also involved in the manufacture of many industrial chemicals and forms derivatives with carboxylic acids, nitriles, alcohols, alkylating agents, carbon disulfide, aldehydes and ketones. It is a basic building block to prepare heterocyclic compound such as imidazolidines. — NCATS
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Earliest trial started Jul 1, 2012 (NCT01798589)
Timeline
No events for the selected filters.
Indications
Approved for
Studied for
Mechanism of action
- GABA receptor subunitACTIVATOR
UNC49B activator
GABA A receptor alpha-1/beta-1/gamma-2 activator
Chemistry & pharmacology
SMILES
NCCN- Mol. weight
- 60.0983 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATS60V9STC53F ↗
- ChEMBLCHEMBL816 ↗
Also known as
- 1,2-diaminoethane
- 1,2-ethanediamine
- edamine
- edamine
- edamine
- ethane-1,2-diamine
- ethyl diamine
- ethylenediamine
- ethylenediamine
- ethylenediamine
- ethylenediamine (1:1) sulfate
- ethylenediamine (1:1) sulfite
- ethylenediamine, 3h-labeled cpd
- ethylenediamine conjugate acid
- ethylenediamine dihydrobromide
- ethylenediamine dihydrochloride
- ethylenediamine dihydrochloride
- ethylenediamine dihydrochloride
- ethylenediamine dihydrogen iodide
- ethylenediamine dihydroiodide
- ethylenediamine dinitrate
- ethylenediamine hydrochloride
- ethylenediamine monohydrochloride
- ethylenediamine phosphate
- ethylenediamine sulfate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05778227 | N/A | Nov 16, 2021 | Dow University of Health Sciences |
| NCT05038059 | N/A | Apr 2, 2020 | Dow University of Health Sciences |
| NCT01798589 | Phase 4 | Jul 1, 2012 | Allerderm |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dow University of Health Sciences | Academic/Hospital | 2 | 2 | 1 | 2020 |
| Allerderm | For profit | 1 | 1 | 1 | 2012 |